NCT06816251CompletedPhase 2
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- First submitted
- 4 Feb 2025
- Start date
- 25 Feb 2025
- Primary completion date
- 18 Nov 2025
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06816251
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 84
- From 25 Feb 2025 to the primary completion date, 18 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of syncope or sustained ventricular tachycardia within 6 months prior to screening.
- Those who have participated in the clinical trial of any drug or medical device within 3 months before screening.
Other illness
- Known or suspected infiltration, hereditary, or storage disorder that can cause myocardial hypertrophy.
- Other conditions that the investigator considers the subject to be unsuitable for participating in this trial.
Other
- Paroxysmal atrial flutter or atrial fibrillation with clinical symptoms at screening.
Who the study is looking for
- Age 18\~85 years old (including boundary value), male or female.
- Body mass index \< 35 kg/m2.
- Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.
- Female subjects of childbearing potential must have a serum pregnancy test prior to the first dose with a negative result and must be non-lactating during the study.
- Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time of signing the informed consent form until 3 months after the last dose of the trial drug, and comply with the relevant contraceptive requirements.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.